Vera Therapeutics Announces Inducement Awards for New Employees
BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA) has made a significant announcement regarding its recent inducement awards given to new employees. On March 6, the Compensation Committee approved the issuance of a non-qualified stock option allowing purchase of 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock. This move aligns with the company’s strategic efforts to attract top talent in the biotech field.
Details of the Inducement Awards
The newly awarded stock options feature an exercise price of $29.30 per share, the closing trading price as of the date of the grant. This stock option plan is structured to incentivize new employees, with vesting occurring over a period of four years. Specifically, 25% of the underlying shares will vest on the first anniversary of the designated vesting commencement date, with the remaining shares vesting monthly over the following 36 months. This strategy ensures that employees have a substantial stake in the company's long-term success.
Additionally, the RSUs awarded will also vest over four years, with 25% vesting on each anniversary of May 20 and again subject to the employee's continued service. These incentives are structured as per the terms of the Inducement Plan and are tailored to support the company's commitment to sustained growth and performance.
About Vera Therapeutics
Vera Therapeutics is at the forefront of developing innovative treatments aimed at addressing serious immunological diseases. The company is dedicated to transforming the standard of care for patients through advanced therapies. Its lead candidate, atacicept, serves as a fusion protein that can be administered subcutaneously once a week. This treatment targets two critical factors, B-cell Activating Factor (BAFF) and APRIL, which are known to stimulate the production of autoantibodies linked to autoimmune conditions, such as IgA Nephropathy (IgAN), also referred to as Berger’s disease, and lupus nephritis.
Expanding Treatment Options
Beyond atacicept, Vera is keenly focused on exploring other diseases that may benefit from the reduction of autoantibodies. Furthermore, Vera is in the process of developing MAU868, a monoclonal antibody aimed at neutralizing BK virus infections, a significant concern in situations such as kidney transplants. The company's commitment to innovation is evident in its retention of global developmental and commercial rights for both atacicept and MAU868.
Licensing and Future Prospects
Vera has also secured an exclusive license agreement with Stanford University for a next-generation fusion protein targeting BAFF and APRIL, identified as VT-109. This product showcases potential therapeutic applications across a broad spectrum of B-cell mediated diseases, signifying Vera's robust pipeline and dedication to ongoing research and development in the field.
Contact Information
For Investor Inquiries:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
For Media Inquiries:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
Frequently Asked Questions
What are the inducement awards announced by Vera Therapeutics?
The inducement awards consist of stock options and restricted stock units aimed at attracting new employees.
When were the inducement awards granted?
Vera Therapeutics granted the awards on March 6, with options and RSUs vesting over a structured four-year period.
What is Vera Therapeutics' lead product candidate?
Vera's lead product candidate is atacicept, aimed at treating immunological diseases by targeting specific factors that promote the disease.
How does atacicept work?
Atacicept blocks the activity of BAFF and APRIL, which are responsible for stimulating B cells that produce harmful autoantibodies.
What future developments can we expect from Vera?
Vera is developing additional therapies, including MAU868 for BK virus infections, enhancing its pipeline for treating a variety of immunological conditions.
